137 related articles for article (PubMed ID: 12054684)
1. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity.
Lotfi K; Månsson E; Peterson C; Eriksson S; Albertioni F
Biochem Biophys Res Commun; 2002 May; 293(5):1489-96. PubMed ID: 12054684
[TBL] [Abstract][Full Text] [Related]
2. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
[TBL] [Abstract][Full Text] [Related]
3. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.
Lotfi K; Karlsson K; Fyrberg A; Juliusson G; Jonsson V; Peterson C; Eriksson S; Albertioni F
Biochem Pharmacol; 2006 Mar; 71(6):882-90. PubMed ID: 16436271
[TBL] [Abstract][Full Text] [Related]
4. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
[TBL] [Abstract][Full Text] [Related]
5. Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.
Månsson E; Liliemark E; Söderhäll S; Gustafsson G; Eriksson S; Albertioni F
Leukemia; 2002 Mar; 16(3):386-92. PubMed ID: 11896543
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes.
Fyrberg A; Albertioni F; Lotfi K
Biochem Biophys Res Commun; 2007 Jun; 357(4):847-53. PubMed ID: 17459340
[TBL] [Abstract][Full Text] [Related]
7. Acute cytotoxicity of arabinofuranosyl nucleoside analogs is not dependent on mitochondrial DNA.
Curbo S; Johansson M; Balzarini J; Lewis LD; Karlsson A
Exp Cell Res; 2009 Sep; 315(15):2539-43. PubMed ID: 19481540
[TBL] [Abstract][Full Text] [Related]
8. Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells.
Curbo S; Zhu C; Johansson M; Balzarini J; Karlsson A
Biochem Biophys Res Commun; 2001 Jul; 285(1):40-5. PubMed ID: 11437369
[TBL] [Abstract][Full Text] [Related]
9. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.
Owens JK; Shewach DS; Ullman B; Mitchell BS
Cancer Res; 1992 May; 52(9):2389-93. PubMed ID: 1568208
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
[TBL] [Abstract][Full Text] [Related]
11. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
12. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases.
Verhoef V; Sarup J; Fridland A
Cancer Res; 1981 Nov; 41(11 Pt 1):4478-83. PubMed ID: 6272978
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells.
Löfgren C; Hjortsberg L; Blennow M; Lotfi K; Paul C; Eriksson S; Albertioni F
Biochem Biophys Res Commun; 2004 Jul; 320(3):825-32. PubMed ID: 15240122
[TBL] [Abstract][Full Text] [Related]
15. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
[TBL] [Abstract][Full Text] [Related]
16. Activity profiles of deoxynucleoside kinases and 5'-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs.
Rylova SN; Albertioni F; Flygh G; Eriksson S
Biochem Pharmacol; 2005 Mar; 69(6):951-60. PubMed ID: 15748706
[TBL] [Abstract][Full Text] [Related]
17. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
Lage H; Dietel M
J Cancer Res Clin Oncol; 2002 Jul; 128(7):349-57. PubMed ID: 12136248
[TBL] [Abstract][Full Text] [Related]
18. Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein.
Huang L; Wang C; Zheng W; Liu R; Yang J; Tang C
Anticancer Drugs; 2007 Oct; 18(9):1075-80. PubMed ID: 17704658
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
Choi CH; Kang G; Min YD
Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines.
Miracco C; Maellaro E; Pacenti L; Del Bello B; Valentini MA; Rubegni P; Pirtoli L; Volpi C; Santopietro R; Tosi P
Int J Oncol; 2003 Jul; 23(1):213-20. PubMed ID: 12792796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
